Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 266

1.

Human and Murine Innate Immune Cell Populations Display Common and Distinct Response Patterns during Their In Vitro Interaction with the Pathogenic Mold Aspergillus fumigatus.

Hellmann AM, Lother J, Wurster S, Lutz MB, Schmitt AL, Morton CO, Eyrich M, Czakai K, Einsele H, Loeffler J.

Front Immunol. 2017 Dec 6;8:1716. doi: 10.3389/fimmu.2017.01716. eCollection 2017.

2.

Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation.

Sadowska-Klasa A, Piekarska A, Prejzner W, Bieniaszewska M, Hellmann A.

Ann Hematol. 2017 Dec 19. doi: 10.1007/s00277-017-3205-5. [Epub ahead of print]

PMID:
29255911
3.
4.

Association of cytokine gene polymorphisms with the complications of allogeneic haematopoietic stem cell transplantation.

Dukat-Mazurek A, Bieniaszewska M, Hellmann A, Moszkowska G, Trzonkowski P.

Hum Immunol. 2017 Nov;78(11-12):672-683. doi: 10.1016/j.humimm.2017.09.005. Epub 2017 Oct 4.

PMID:
28987962
5.

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J.

J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.

PMID:
28930494
6.

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.

Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, Stenke L, Thaler J, Thielen N, Verhoef G, Voglova J, Ossenkoppele G, Hochhaus A, Hjorth-Hansen H, Mustjoki S, Sopper S, Giles F, Porkka K, Wolf D, Gjertsen BT.

Haematologica. 2017 Aug;102(8):1361-1367. doi: 10.3324/haematol.2017.167080. Epub 2017 May 18.

7.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

8.

Recurrent bowel-blood translocations of Escherichia coli with the unique virulence characteristics over three-year period in the patient with acute myeloid leukaemia - case report.

Krawczyk B, Śledzińska A, Piekarska A, Hellmann A, Kur J.

J Appl Genet. 2017 Aug;58(3):415-418. doi: 10.1007/s13353-017-0393-6. Epub 2017 Mar 21.

9.

Fecal impaction as the first manifestation of Addisonian crisis.

Hellmann AR, Głowacki J, Śledziński Z, Sworczak K.

Pol Arch Intern Med. 2017 Feb 28;127(2):125-126. doi: 10.20452/pamw.3951. Epub 2017 Feb 28. No abstract available.

PMID:
28267136
10.

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.

Hochhaus A, Mahon FX, le Coutre P, Petrov L, Janssen JJWM, Cross NCP, Rea D, Castagnetti F, Hellmann A, Rosti G, Gattermann N, Coronel MLP, Gutierrez MAE, Garcia-Gutierrez V, Vincenzi B, Dezzani L, Giles FJ.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1225-1233. doi: 10.1007/s00432-017-2359-9. Epub 2017 Feb 21.

11.

[Positionpaper on Telemonitoring in Sleep-Related Breathing Disorders].

Randerath W, Bögel M, Franke C, Hellmann A, Jany B, Nilius G, Penzel T, Voshaar T, Wiater A.

Pneumologie. 2017 Feb;71(2):81-85. doi: 10.1055/s-0042-124083. Epub 2017 Feb 21. German.

PMID:
28222476
12.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G.

Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.

13.

Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study.

Sacha T, Góra-Tybor J, Wąsak-Szulkowska E, Kyrcz-Krzemień S, Mędraś E, Becht R, Bober G, Kotowska A, Wącław J, Hellmann A.

Clin Lymphoma Myeloma Leuk. 2017 May;17(5):283-295. doi: 10.1016/j.clml.2017.01.001. Epub 2017 Jan 10.

PMID:
28185798
14.

Efficacy and safety of a VWF/FVIII concentrate (wilate® ) in inherited von Willebrand disease patients undergoing surgical procedures.

Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM; Wonders Study Investigators.

Haemophilia. 2017 Mar;23(2):264-272. doi: 10.1111/hae.13106. Epub 2016 Dec 27.

PMID:
28026130
15.

The current status and the future of internal medicine: a voice in the discussion.

Hellmann A.

Pol Arch Med Wewn. 2016 Dec 22;126(12):1054-1057. doi: 10.20452/pamw.3737. Epub 2016 Dec 22. No abstract available.

16.

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.

Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U.

Br J Haematol. 2017 Feb;176(4):618-628. doi: 10.1111/bjh.14464. Epub 2016 Dec 15.

17.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators.

N Engl J Med. 2016 Oct 6;375(14):1319-1331.

18.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.

PMID:
27568522
19.

A Long-Term Follow-Up Investigation of Endobronchial Valves in Emphysema (the LIVE Study): Study Protocol and Six-Month Interim Analysis Results of a Prospective Five-Year Observational Study.

Skowasch D, Fertl A, Schwick B, Schäfer H, Hellmann A, Herth FJ; LIVE Study Investigators.

Respiration. 2016;92(2):118-26. doi: 10.1159/000448119. Epub 2016 Aug 24.

20.

Treatment of the Lymphocele After Kidney Transplantation: A Single-center Experience.

Bzoma B, Kostro J, Dębska-Ślizień A, Hellmann AR, Zadrożny D, Śledziński Z, Rutkowski B.

Transplant Proc. 2016 Jun;48(5):1637-40. doi: 10.1016/j.transproceed.2016.03.025.

PMID:
27496462

Supplemental Content

Loading ...
Support Center